Acadia Pharmaceuticals vs ANI Pharmaceuticals
Add, change or remove companies; up to four.
The short version
- Acadia Pharmaceuticals is the larger business, with $1.1B of revenue in fiscal 2025 against $883M for ANI Pharmaceuticals.
- ANI Pharmaceuticals grew revenue faster (43.8%, against 11.9%).
- ANI Pharmaceuticals kept more of each dollar of sales as operating profit (12.6% operating margin, against 9.8%).
- ANI Pharmaceuticals turned more of its sales into free cash flow (19.4% FCF margin, against 9.8%).
- Investors pay more for each dollar of ANI Pharmaceuticals’s earnings: a P/E of 15.7x against 8.8x for Acadia Pharmaceuticals.
| Latest fiscal year | ACAD · FY25 | ANIP · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $1.6B |
| Revenue | $1.1B | $883M |
| Free cash flow | $105M | $171M |
| Net income | $391M | $78.3M |
| Growth | ||
| Revenue growth | 11.9% | 43.8% |
| 5-year growth | 19.4% | 33.5% |
| Share count change | 2.1% | 9.9% |
| Profitability | ||
| Gross margin | 91.7% | — |
| Operating margin | 9.8% | 12.6% |
| Net margin | 36.5% | 8.9% |
| FCF margin | 9.8% | 19.4% |
| Return on capital | — | 15.9% |
| Return on equity | 39.9% | 16.6% |
| Balance sheet | ||
| Net debt | — | $23.7M |
| Net debt / EBITDA | — | 0.1x |
| Dividends and buybacks | $0.0M | $13.4M |
| Valuation & quality | ||
| P/E | 8.8x | 15.7x |
| Piotroski F-score | — | 6 |
FY16
ACAD $17.3M
ANIP $129M
FY17
ACAD $125M
ANIP $177M
FY18
ACAD $224M
ANIP $202M
FY19
ACAD $339M
ANIP $207M
FY20
ACAD $442M
ANIP $209M
FY21
ACAD $484M
ANIP $216M
FY22
ACAD $517M
ANIP $316M
FY23
ACAD $726M
ANIP $487M
FY24
ACAD $958M
ANIP $614M
FY25
ACAD $1.1B
ANIP $883M
ACAD
ANIP
FY16
ACAD −1,574.1%
ANIP 15.6%
FY17
ACAD −234.1%
ANIP 16.0%
FY18
ACAD −110.6%
ANIP 17.5%
FY19
ACAD −72.7%
ANIP 7.9%
FY20
ACAD −64.9%
ANIP −7.7%
FY21
ACAD −35.2%
ANIP −18.4%
FY22
ACAD −43.2%
ANIP −11.2%
FY23
ACAD −10.1%
ANIP 9.7%
FY24
ACAD 24.1%
ANIP 0.1%
FY25
ACAD 9.8%
ANIP 12.6%
ACAD
ANIP
FY16
ACAD −$210M
ANIP $22.9M
FY17
ACAD −$219M
ANIP $29.1M
FY18
ACAD −$170M
ANIP $61.3M
FY19
ACAD −$152M
ANIP $39.0M
FY20
ACAD −$144M
ANIP $9.1M
FY21
ACAD −$127M
ANIP $0.8M
FY22
ACAD −$114M
ANIP −$40.1M
FY23
ACAD $16.7M
ANIP $110M
FY24
ACAD $157M
ANIP $47.8M
FY25
ACAD $105M
ANIP $171M
ACAD
ANIP
FY16
ACAD —
ANIP 5.3%
FY17
ACAD —
ANIP 5.3%
FY18
ACAD —
ANIP 11.0%
FY19
ACAD —
ANIP 5.8%
FY20
ACAD —
ANIP −3.6%
FY21
ACAD —
ANIP −7.0%
FY22
ACAD —
ANIP −5.2%
FY23
ACAD —
ANIP 8.5%
FY24
ACAD —
ANIP 0.1%
FY25
ACAD —
ANIP 15.9%
ACAD
ANIP
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.